CAMP4 Therapeutics

Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M

Upstream Bio will use its IPO haul to continue clinical testing of verekitug, which it contends could be a better treatment option for severe asthma compared to a commercialized Amgen and AstraZeneca drug. CAMP4 Therapeutics and CeriBell also priced IPOs to join the public markets.

By Frank Vinluan

BioPharma, Artificial Intelligence

Northpond, 5AM Ventures lead $45M funding for CAMP4’s trek to new RNA therapies

CAMP4 Therapeutics is developing a new kind of RNA therapy that treats disease by upregulating gene expression. The startup has raised $45 million as CEO Josh Mandel-Brehm steers toward clinical trials expected to begin next year in liver and brain diseases.

By Frank Vinluan